Fluid Overload Quantification in Septic Shock (FOTOShock)

Body Composition Monitor to Quantify Fluid Overload Related to Vascular Leak in Septic Shock Patients

Fluid management in septic shock patients remain a great challenge. Insufficient fluid filling lead to hypovolemia, organ failure and increased death, whereas fluid overload was associated to an increased morbidity and mortality in several studies.

Several invasive and non invasive strategies have been developed during the past years to monitor the hemodynamic state of septic shock patients, but no method has been validated to objectively quantify fluid overload in septic shock patients.

The Body Composition Monitor (BCM) allow for measurement of total body water (TBW), extracellular water (ECW) and intracellular water (ICW) volumes using bioimpedancemetry. The BCW is daily used in patients who undergo renal dialysis to assess the effectiveness of fluid removal. The BCM has never been validated in septic shock patients.

The aim of the study is to investigate the accuracy of the BCM to measure the variation of the TBW during a fluid challenge of 500 ml of saline during the early phase of septic shock.

Study Overview

Status

Recruiting

Detailed Description

Patients suffering from septic shock admitted in our critical care unit for less than 24 hours will be eligible. TBW, ECW and ICW volumes will be measured using the BCM just before (T0), just at the end (T1) and 1 h after the end (T2) of a fluid challenge of 500 ml of saline. Fluid responsiveness will be assessed using trans thoracic echocardiography (TTE). TTE will be performed at T0, T1 and T2. Blood samples will be obtained at T0, T1 and T2 to dose biomarkers of endothelial dysfunction and of capillary leak. The effectiveness of fluid challenge on microcirculation will be investigated by measuring the tissue perfusion index of the urethral mucosa using the IKORUS UP device.

Patients will be followed until Day 28 after admission in the critical care unit.

Study Type

Observational

Enrollment (Anticipated)

64

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Besançon, France, 25030
        • Recruiting
        • Centre Hospitalier Universitaire de Besançon
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

ICU patient requiring fluid resuscitation for septic shock

Description

Inclusion Criteria:

  • Patient aged from 18 to 80 years old
  • Admitted to ICU for septic shock for less than 24 h
  • Fluid resuscitation decided by intensivist
  • Patient affiliated to a social security system or recipient of a such system
  • Patient/proxy not opposed to the study

Exclusion Criteria:

  • Subject with amputation of 1 or more limbs
  • Body mass index > 35 kg.m-2 ou < 18 kg.m-2
  • Impossibility of setting up an arterial catheter for invasive blood pressure monitoring and / or a central venous catheter in the upper cava territory
  • Patient with pacemaker and / or implantable cardioverter defibrillator
  • Quality of cardio echo image insufficient to allow studied parameters measurement
  • Moribund subject ( life expectancy expected less than 48 hours)
  • Uncontrolled intracranial hypertension (intracranial pressure ≥ 20 mm Hg by ICP monitoring or by a pulsatility index ≥ 1.30 in the transcranial Doppler)
  • Patient under ECMO/ECLS
  • Legal incapacity or limited legal capacity
  • Subject without health insurance
  • Pregnant woman
  • Subject being in the exclusion period of another study or provided for by the "National Volunteer File"

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the accuracy of the BCM to measure the variation of the TBW volume during a fluid challenge.
Time Frame: 10 minutes
The variation of the TBW volume measured by the BCM will be compared to the variation of the volume of fluids (fluid input minus fluid output) during a fluid challenge of 500 ml of saline. Fluid input will be the sum of the volume of all fluids and drugs delivered during the fluid challenge (including enteral nutrition). Fluid output will be the sum of all loss of fluid (surgical drain, urine output) during the fluid challenge.
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To describe the variation of the ECW volume measured by the BCM during a fluid challenge of 500 ml of saline.
Time Frame: 10 minutes
The variation of the ECW volume during a fluid challenge of 500 ml of saline will be the difference between the ECW volume measured à T0 (just before the fluid challenge) and the ECW volume measured at T1 (just after the end of the fluid challenge).
10 minutes
To describe the variation of the ECW volume on TBW volume ratio during a fluid challenge of 500 ml of saline.
Time Frame: 10 minutes
ECW and TBW volumes will be measured using the BCM just before the fluid challenge (T0) and just after the end of the fluid challenge (T1). The ECW volume on TBW volume ratio (ECW/TBW ratio) will be calculated at T0 and at T1. The variation of the ECW/TBW ration will be the difference between the ECW/TBW ratio measured at T0 and the ECW/TBW ratio measured at T1.
10 minutes
To compare the phase angle value measured at T0 by the BCM between responders and non responders at T1.
Time Frame: 10 minutes
Fluid responsiveness at T1 will be defined by an increased of the stroke volume > 10% between T0 and T1. Stroke volume will be measured using trans thoracic echocardiography. The phase angle value at T0 will be compared between responders (patients with an increase of the stroke volume > 10%) and non responders.
10 minutes
To describe the relationship between the phase angle value measured at T0 by the BCM and the capillary leak index.
Time Frame: 10 minutes
The capillary leak index is defined by the following ratio: (blood C-reactive protein*100)/(blood albumin).
10 minutes
To compare the ECW/TBW ratio at T0 between responders and non responders at T1.
Time Frame: 10 minutes
10 minutes
To compare the TBW volume at T0 between responders and non responders at T2.
Time Frame: 70 minutes
Fluid responsiveness will be assessed at T2 (1 h after the end of the fluid challenge) using transthoracic echocardiography (TTE). Fluid responsiveness at T2 will be defined by an increased of the stroke volume > 10% compared to baseline (T0).
70 minutes
To compare the ECW/TBW ratio at T0 between responders and non responders at T2.
Time Frame: 70 minutes
Fluid responsiveness will be assessed at T2 (1 h after the end of the fluid challenge) using transthoracic echocardiography (TTE). Fluid responsiveness at T2 will be defined by an increased of the stroke volume > 10% compared to baseline (T0).
70 minutes
To compare the ECW/TBW ratio at T2 between responders and non responders at T2.
Time Frame: 70 minutes
Fluid responsiveness will be assessed at T2 (1 h after the end of the fluid challenge) using transthoracic echocardiography (TTE). Fluid responsiveness at T2 will be defined by an increased of the stroke volume > 10% compared to baseline (T0). ECW/TBW ratio will be calculated at T2 from the ECW and TBW volumes measured using the BCM at T2 (1 h after the end of fluid challenge).
70 minutes
To describe the variation of the tissue perfusion index of the urethral mucosa (uPI) measured using the IKORUS UP device during the fluid challenge of 500 ml of saline.
Time Frame: 70 minutes
The uPI will be continuously measured during the fluid challenge and until 1 hours after the end of the fluid challenge. The uPI will be measured using the IKORUS UP device.
70 minutes
To describe the relationship between blood biomarkers of endothelial dysfunction and fluid responsiveness.
Time Frame: 70 min
Blood biomarkers of endothelial dysfunction will be measured from blood samples obtained at T0, T1 and T2. Fluid responsiveness will be assessed using TTE. Fluid responsiveness will be defined by an increased of the stroke volume > 10% compared to baseline (T0).
70 min
To describe the relationship between blood biomarkers of capillary leak and fluid responsiveness.
Time Frame: 70 minutes
Blood biomarkers of capillary leak will be measured from blood samples obtained at T0, T1 and T2. Fluid responsiveness will be assessed using TTE. Fluid responsiveness will be defined by an increased of the stroke volume > 10% compared to baseline (T0).
70 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Anticipated)

December 30, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

October 1, 2019

First Submitted That Met QC Criteria

October 1, 2019

First Posted (Actual)

October 3, 2019

Study Record Updates

Last Update Posted (Actual)

March 30, 2023

Last Update Submitted That Met QC Criteria

March 29, 2023

Last Verified

June 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Shock, Septic

3
Subscribe